Marie Bosslett, Assistant Editor

In case you missed it, this week we had news about roflumilast's expanded access for children as young as 2, LP-10 for oral lichen planus, SYX-5219's IND clearance, and more.

Amy Lewis, MD, integrates Glo2Facial into her practice to enhance patient relationships and promote early skin health through innovative aesthetic treatments.

A study reveals ixekizumab's effectiveness in treating mild to moderate plaque psoriasis, showing superior PASI responses and improved long-term outcomes.

Discover how the Glo2Facial revolutionizes aesthetic dermatology with innovative skin oxygenation and customizable treatments for radiant, youthful skin.

New research highlights the psychosocial impact of rosacea on Chinese patients, linking lifestyle factors and comorbidities to quality of life.

Explore real-world psoriasis management insights from Anthony Nuara, MD, PhD, focusing on patient-centered approaches and innovative treatments like tildrakizumab.

A new trial reveals that combining Excimer laser with JAK inhibitors significantly enhances vitiligo treatment outcomes, ensuring safety and durability.

This review of the latest dermatologic studies highlights new research on mitigating irritation from 0.1% retinol, OTC therapies for alopecia, the perception of skin lesions by HCPs in the delivery room, and more.

New research highlights the link between isotretinoin dosage and increased chronic hand eczema, emphasizing the need for careful monitoring during acne treatment.

Lipella Pharmaceuticals' LP-10 shows promise as a targeted treatment for OLP, offering safety and efficacy in recent trials, according to Michael Chancellor, MD.

Sitryx Therapeutics advances SYX-5219 for moderate to severe AD, aiming for a first-in-class oral treatment with potential for lasting disease remission.

Brian Kim, MD, FAAD, explores the transformative role of neuroimmunology in dermatology, urging a shift towards systems-level therapeutic strategies.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

In case you missed it, this week we had news about the FDA approvals of guselkumab for pediatric plaque psoriasis and PsA, along with remibrutinib for CSU, LEO Pharma's acquisition of spesolimab for GPP, and more.

Brian Kim, MD, FAAD, explores the Cell Symposia: Neuro-immune Axis, highlighting neuroimmunology's impact on dermatology and systemic medicine.

WHO includes adalimumab and ustekinumab for psoriasis, plus sunscreen for albinism, enhancing global skin health and access to essential treatments.

Lisa Espinoza, MD, highlights the importance of patient education and tailored HA filler treatments for achieving natural cosmetic results.

Heather Gates, PA-C, brings her dermatology expertise into a conference management business to enhance education for professionals of all levels.

Lisa Espinoza, MD, discusses key insights from Allergan's Hyaluronic Acid Injectable Fillers Report, highlighting patient satisfaction and evolving aesthetic trends.

Patient advocate Danielle Jonas shares her journey with atopic dermatitis, emphasizing the importance of trusted products and clinician support during Eczema Awareness Month.

World Urticaria Day raises awareness about chronic spontaneous and inducible urticaria, highlighting treatment advancements and patient challenges.

Dermatology Times has compiled a list of dermatological meetings taking place during the month of October.

Explore insights from Renata Block DMSc, MMS, PA-C, and James Del Rosso, DO, on interpreting clinical trial data in dermatology for enhanced patient care and outcomes.

Dermatology Times is looking back on the top stories in dermatology from the month of September.

Miiskin integrates generative AI into dermatology, enhancing efficiency and patient access while reducing clinician workload and administrative tasks.

Learn more about the in-depth topics covered in the September 2025 print issue of Dermatology Times.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

In case you missed it, this week we had news about upadacitinib's phase 3 efficacy in alopecia, APG777 as a potential breakthrough in AD, the latest conference insights, and more.

Explore the latest advancements and expert insights from the Maui Derm NP+PA Fall 2025 conference in Nashville, Tennessee.

Elena Hawryluk, MD, PhD, shares groundbreaking insights on pediatric dermatology and melanoma management at Maui Derm NP+PA, emphasizing innovative treatments.